DAHUA-TECHNOLOGY
6.4.2022 15:47:08 CEST | Business Wire | Press release
Dahua Technology, a world leading video-centric smart IoT solution and service provider, successfully held an online event today to celebrate the 10th anniversary of its self-developed HDCVI technology. With the theme of “Blazing a trail to the Over-Coax AI era”, Dahua showcased the latest achievements of the HDCVI technology enhanced by AI, and shared the success of its technological innovation and business development with global partners and customers, achieving another milestone in the Over-Coax industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005601/en/
Since introducing its self-developed HDCVI technology in 2012, Dahua has been on the forefront of delivering long-distance HD transmission and seamless upgrading experience for analog system users. “This year, we will provide users with more comprehensive and easy-to-use Over-Coax AI intelligent solutions,” said Jason Zhao, Dahua Senior Vice President and General Manager of Overseas Business Center.
At the event, Dahua announced the four core technologies of its brand new HDCVI TEN in 2022, including AI-for-all, Scheduled AI, Smart Dual Illuminators, and Real 5MP 16:9.
Dahua is helping to usher in the Over-Coax AI era by being one of the first innovators in the industry to release a full line up of AI-enabled XVRs. Following the launch of the groundbreaking entry-level AI XVR, Cooper-I Series last year, Dahua has been pushing its ‘AI-for-all’ concept to the next level, allowing users to enjoy SMD Plus, Perimeter Protection, AI Coding and other useful AI features at a friendly cost.
Moreover, HDCVI TEN is also packed with a handful of new and exciting technologies that can greatly improve the operation efficiency of analog systems and expand the range of suitable application scenarios. For instance, the Scheduled AI function of XVR5000-4KL-I3 series supports automatic switching of multiple AI functions according to the time period set by the user, making it ideal for villas, retail stores, public swimming pools, etc. At the same time, the Smart Dual Illuminators feature integrates smart target detection and full-color monitoring for effective information collection in low-light conditions while helping mitigate light pollutions at night. In addition, the Real 5MP cameras with 16:9 video output provide undistorted image performance with optimized visual experience, which can be deployed in parks, casinos, museums, and other scenarios that require clarity and fluidity in their video surveillance.
To learn more about the launch event, click here to watch the replay or check out Dahua Blog .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005601/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom